Search
Huiyu Pharmaceutical: HY0001a Injection Receives Approval for Drug Clinical Trial
3 week ago /
Read about 0 minute
Author：小编
On June 20, Huiyu Pharmaceutical announced that its wholly-owned subsidiary, Huiyu Haiyue, has secured approval from the National Medical Products Administration to initiate clinical trials for its groundbreaking biological drug, HY0001a Injection (R&D code "HY-0001"), for the treatment of advanced solid tumors. This drug represents a Class 1 innovative antibody-drug conjugate, independently developed by the company. Notably, there are no existing products globally that target the same biomarker, positioning HY0001a as the world's first clinical drug specifically designed to address this biomarker.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
